Dear Editor Combinatorial immunotherapy has provided patients with advanced hepatocellular carcinoma(HCC)the potential for long-term survival.However,sustained responses are seen only in a minority of patients[1].Thus...Dear Editor Combinatorial immunotherapy has provided patients with advanced hepatocellular carcinoma(HCC)the potential for long-term survival.However,sustained responses are seen only in a minority of patients[1].Thus,there is an unmet need for precision modeling to understand the different responses and uncover predictive biomarkers for treatment stratification.展开更多
基金supported by the National Institutes of Health grant R01-CA-249929-06A1 to KHKsupport from the Molecular Pathology&Imaging Core(MPIC)of the UPenn Center for Molecular Studies in Digestive and Liver Diseases(P30 DK050306)the Comparative Pathology Core,the Wistar Institute Genomics Facility,the Functional Genomics Core of the UPenn Diabetes Research Center(P30 DK019525).
文摘Dear Editor Combinatorial immunotherapy has provided patients with advanced hepatocellular carcinoma(HCC)the potential for long-term survival.However,sustained responses are seen only in a minority of patients[1].Thus,there is an unmet need for precision modeling to understand the different responses and uncover predictive biomarkers for treatment stratification.
